Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

ANCA-associated renal vasculitis - an update.

Tesar V, Hruskova Z.

Contrib Nephrol. 2013;181:216-28. doi: 10.1159/000348634. Epub 2013 May 8. Review.

PMID:
23689583
2.

Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.

Jones RB.

Nephron Clin Pract. 2014;128(3-4):243-9. doi: 10.1159/000368580. Epub 2014 Nov 14. Review.

3.

Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?

Tesar V.

Nephrol Dial Transplant. 2015 Jul;30(7):1088-90. doi: 10.1093/ndt/gfv215. Epub 2015 May 21.

PMID:
25999373
4.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS).

Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4.

PMID:
25739829
5.

B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.

Kallenberg CG, Hauser T.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i119-22. doi: 10.1093/ndt/gfv056. Epub 2015 Mar 9. Review.

PMID:
25753806
6.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Nossent JC.

N Engl J Med. 2010 Nov 18;363(21):2072; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA2. No abstract available.

PMID:
21083400
7.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Karassa FB.

N Engl J Med. 2010 Nov 18;363(21):2073; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA4. No abstract available.

PMID:
21083398
8.

Impact of rituximab trials on the treatment of ANCA-associated vasculitis.

Alberici F, Jayne DR.

Nephrol Dial Transplant. 2014 Jun;29(6):1151-9. doi: 10.1093/ndt/gft318. Epub 2013 Oct 14. Review.

PMID:
24126571
9.

Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?

Tesar V, Hruskova Z.

Expert Opin Pharmacother. 2015;16(11):1683-702. doi: 10.1517/14656566.2015.1059822. Epub 2015 Jul 6. Review.

PMID:
26149512
10.

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.

Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X.

Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Review.

PMID:
22146313
11.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Schönermarck U, Rau S, Fischereder M.

N Engl J Med. 2010 Nov 18;363(21):2072; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA1. No abstract available.

PMID:
21083401
12.

Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?

Kallenberg CG.

Curr Opin Rheumatol. 2014 May;26(3):292-8. doi: 10.1097/BOR.0000000000000049. Review.

PMID:
24646946
13.

Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.

Zand L, Specks U, Sethi S, Fervenza FC.

Adv Chronic Kidney Dis. 2014 Mar;21(2):182-93. doi: 10.1053/j.ackd.2014.01.009. Review.

PMID:
24602467
14.

Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.

Hebert LA, Ardoin S, Shim RL.

N Engl J Med. 2010 Nov 18;363(21):2072-3; author reply 2073-4. doi: 10.1056/NEJMc1009101#SA3. No abstract available.

PMID:
21083399
15.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.

Santana AN, Woronik V, Halpern AS, Barbas CS.

J Bras Pneumol. 2011 Nov-Dec;37(6):809-16. Review. English, Portuguese.

16.

Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis.

Asamiya Y, Moriyama T, Takano M, Iwasaki C, Kimura K, Ando Y, Aoki A, Kikuchi K, Takei T, Uchida K, Nitta K.

Intern Med. 2010;49(15):1587-91. Epub 2010 Aug 2.

17.

[Renal disease in ANCA-associated vasculitis].

Fumeaux D, de Seigneux S, Chizzolini C, Martin PY.

Rev Med Suisse. 2014 Feb 26;10(419):493-7. Review. French.

PMID:
24665659
18.

Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.

Rutgers A, Kallenberg CG.

Curr Opin Rheumatol. 2012 May;24(3):245-51. doi: 10.1097/BOR.0b013e3283529756. Review.

PMID:
22410545
19.

ANCA-associated vasculitides--advances in pathogenesis and treatment.

Chen M, Kallenberg CG.

Nat Rev Rheumatol. 2010 Nov;6(11):653-64. doi: 10.1038/nrrheum.2010.158. Epub 2010 Oct 5. Review.

PMID:
20924413
20.

Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis.

Sinico RA, Di Toma L, Radice A.

Autoimmun Rev. 2013 Feb;12(4):477-82. doi: 10.1016/j.autrev.2012.08.006. Epub 2012 Aug 16. Review.

PMID:
22921791

Supplemental Content

Support Center